Robert Z. Orlowski · @Myeloma_Doc · Oct 17, 2026“#Myeloma Paper of the Day: IFM 2026 recommendations for first-line treatment of newly diagnosed myeloma include triplets (DRd) and quadruplets (Isa-VRd, Dara-VRd); mathematical modeling projects median PFS of 100-205 months: https://t.co/10fMzlehFD. #mmsm”
58 likes · 12 reposts · 1 reply · 2,942 viewsView post ↗Full Multiple Myeloma & Plasma Cell Disorders coverage in today's digest →A real-world analysis in Stage III NSCLC found the median time to consolidative immunotherapy was 84 days from the start of CRT, with delays associated with insurance status and treatment at non-academic centers. The design of the Phase III JCOG2510 (PRIME-CRT) trial is also being highlighted, investigating induction pembrolizumab plus chemotherapy before cCRT and consolidative durvalumab in unresectable locally advanced NSCLC.
“💡Our real-world analysis showed median time to consolidative #immunotherapy of 84 days from CRT start (~42days post-CRT completion) in Stage III #NSCLC (2018-2021). Uninsured, Medicaid, and tx at non-academic independently associated w/ longer time to intiation #ASCOQLTY26”
— @ChaewonHwangMD · Immunotherapy Timing · View post ↗
“🇯🇵 JCOG2510 (PRIME-CRT) Phase III ☢️ Can induction Chemo-IO improve survival in unresectable locally advanced NSCLC? 🔵 cCRT → Durvalumab vs. 🔴 Chemo + Pembrolizumab (2 cycles) → cCRT → Durvalumab 🎯 N=212 | Primary endpoints: PFS & OS”
— @M_Torasawa · JCOG2510 Trial Design · View post ↗The Phase 3 HELEN-Trio 011 trial, published in Annals of Oncology, showed that adding the PD-1 inhibitor camrelizumab (not approved in the US or EU) to docetaxel and carboplatin improved pathological complete response (pCR) rates from 45.4% to 57.5% for patients with stage II–III triple-negative breast cancer (TNBC). The breast oncology community views this anthracycline-sparing chemoimmunotherapy as a promising de-escalation strategy, but notes that event-free survival (EFS) data is still immature and the trial did not include a direct comparison to the KEYNOTE-522 regimen.
“💡 Why it matters: An anthracycline-free chemoimmunotherapy strategy improves pCR without a substantial increase in severe toxicity. ⚠️ Caution: EFS remains immature. No direct comparison with KEYNOTE-522. 🎯 Verdict: Promising de-escalation strategy, but not yet a replacement for KEYNOTE-522.”
— @DrRishabhOnco · HELEN-Trio 011 for TNBC · View post ↗
“If a Her2 positive patient does not respond well to THP-T’dxd its one of 2 things. 1. Its really an aggressive form of TNBC or a very luminal non-Her2 enriched tumor. 2. It’s primary refractory disease, which is quite rare (almost always ER negative) and carries a terrible prognosis.”
— @Dr_RShatsky · HER2+ treatment resistance · View post ↗📌 Amplified by @KolPulseAI
“Breast cancer survivorship care goes beyond surveillance!”
— @YAbdouMD · Survivorship care · View post ↗New ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of gastric and esophageal cancer are now available. The guidelines emphasize the key role of biomarker testing, including for HER2, MSI, CLDN18.2, and PD-L1.
“Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @Annals_Oncology https://t.co/q8W867xpij 👉get the latest updates 👉Biomarker testing (e.g. HER2, MSI, CLDN18.2, PD-L1) key”
— @ArndtVogel · Gastric/Esophageal Cancer Biomarkers · View post ↗
“💡 Exercise may prevent both colon cancer recurrence and second cancers.”
— @DraMartinezLago · Exercise in Colon Cancer · View post ↗
“Young-onset colorectal cancer is rising, and CRC demands focus. @MDAndersonNews has created a dedicated Department of Colorectal Medical Oncology to meet that challenge.”
— @skopetz · Young-Onset Colorectal Cancer · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The Oct 14, 2026 FDA expansion of Anktiva plus BCG to BCG-unresponsive, high-grade papillary-only NMIBC (see Regulatory above) leads GU news. In VHL disease, Dr. Maite Bourlon noted that belzutifan gained FDA approval five years ago and called for its approval in Mexico.
“5-years ago #belzutifan got FDA approval, we all agree that it urges to have approval in🇲🇽”
— @BourlonMaite · Belzutifan Access · View post ↗A pooled analysis in Blood Advances of 256 patients with relapsed/refractory AL amyloidosis showed high hematologic overall response rates for investigational BCMA-directed therapies, including 92% for CAR-T and 89% for bispecific antibodies. Dr. Ankit Kansagra highlighted the 41% cardiac response rate in evaluable patients as a key finding, though noted the analysis is descriptive with short follow-up. Separately, Dr. Robert Z. Orlowski shared new IFM 2026 recommendations for first-line newly diagnosed myeloma, which include triplet (DRd) and quadruplet (Isa-VRd, Dara-VRd) regimens, with mathematical modeling projecting a median PFS of 100–205 months.
“92%. 89%. 68%. Those are the pooled hematologic ORRs for CAR-T, bispecifics and belantamab in relapsed/refractory AL amyloidosis, from the Blood Advances analysis Muzaffar flagged (Alqazaqi, Sanchorawala, Al Hadidi and colleagues).”
— @kansagraMD · AL Amyloidosis · View post ↗“#Myeloma Paper of the Day: IFM 2026 recommendations for first-line treatment of newly diagnosed myeloma include triplets (DRd) and quadruplets (Isa-VRd, Dara-VRd); mathematical modeling projects median PFS of 100-205 months: https://t.co/10fMzlehFD.”
— @Myeloma_Doc · NDMM Treatment Recommendations · View post ↗“1. Cardiac responses in 41% of evaluable pts (49% with BsAb, 40% with CAR-T). In AL the clone is only half the story. The heart is what kills pts, so this number matters more to me than the ORR”
— @kansagraMD · AL Amyloidosis · View post ↗
“@kansagraMD @mtmdphd Agree with target switch but also a good time to sequence bcma to see if you can go back with tce/cellmod combo. Plasma seq can give you the answer”
— @SagarLonialMD · Treatment Sequencing · View post ↗A single-center series of 124 patients with advanced-stage high-grade B-cell lymphoma with MYC rearrangement found DA-R-EPOCH was associated with better overall survival than R-CHOP-based therapy, with a 2-year OS of 59.8%. Dr. Michael Dickinson's summary noted a 10.1% CNS relapse rate and highlighted that the MYC/BCL6-rearranged subtype experienced more CNS relapse and rapid progression. Other topics of discussion include updates on targeted therapies for AML, such as menin inhibitors.
“DA-R-EPOCH associated with better OS than R-CHOP-based therapy.”
— @mike_dickinson1 · High-Grade B-Cell Lymphoma · View post ↗
“Updates on the use of Menin inhibitors in AML.. and the importance to understand the resistance mecanisms”
— @AdePejanja · Menin Inhibitors in AML · View post ↗
“Early Integration of CAR T-Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors”
— @smbenlazar · CAR-T in Mantle Cell Lymphoma · View post ↗